InnovAge Holding Corp. Liquidation Value

INNV Healthcare Services

Cash & Equivalents

$95.54M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $95.54M
Total Obligations: -$297.22M
$-201.69M
Per share: $-1.49
Period: 2026-03-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $95.54M
AR: $28.58M
Total Obligations: -$297.22M
$-173.10M
Per share: $-1.28
Period: 2026-03-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $95.54M
AR: $28.58M
Inventory: N/A
Total Obligations: -$297.22M
$-173.10M
Per share: $-1.28
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Inventory: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-201.69M$-1.49
Liquid Liquidation Value$-173.10M$-1.28
Operating Liquidation Value$-173.10M$-1.28

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-08. View on SEC EDGAR →

Cash & Equivalents$95.54M
Accounts Receivable$28.58M
InventoryN/A
Current Liabilities$195.89M
Long-term Debt (?)$55.43M
Op. Lease Liability (?)$20.63M
Finance Lease (?)$5.45M
Shares Outstanding135.7M

Explore all 151 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$95.54M$28.58MN/AN/A$195.89M$55.43M$20.63M$5.45M
2025-12-31$83.20M$21.30MN/AN/A$144.70M$55.99M$21.64M$5.41M
2025-09-30$67.15M$23.17MN/AN/A$138.49M$56.15M$22.82M$6.31M
2025-06-30$64.13M$36.37MN/AN/A$164.81M$57.46M$23.92M$7.54M
2025-03-31$60.45M$44.40MN/AN/A$225.32M$1.76M$23.68M$8.80M
2024-12-31$46.08M$49.76MN/AN/A$144.97M$59.80M$23.85M$8.96M
2024-09-30$39.02M$46.73MN/AN/A$131.35M$60.64M$24.99M$10.85M
2024-06-30$56.95M$48.11MN/AN/A$138.60M$61.48M$26.27M$12.74M

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-08 View
2025-12-31 10-Q 2026-02-03 View
2025-09-30 10-Q 2025-11-04 View
2025-06-30 10-K 2025-09-09 View
2025-03-31 10-Q 2025-05-06 View
2024-12-31 10-Q 2025-02-04 View
2024-09-30 10-Q 2024-11-05 View
2024-06-30 10-K 2024-09-10 View

AI Insights

AI Insight·Generated 2026-05-09

InnovAge Holding Corp. (INNV) reported a balance sheet as of March 31, 2026 with total assets of $547.4M against total liabilities of $288.5M, producing GAAP book equity of $232.8M (including noncontrolling interests). Under liquidation-value methodology, recovery to equity is materially negative, consistent with MFFAIS-computed CLV/LLV of approximately -$153M to -$182M. The asset side haircut is severe: goodwill of $142.0M carries zero liquidation value; intangibles net of $3.4M similarly zero. PP&E gross of $275.0M with accumulated depreciation of $109.7M yields net book of $165.4M, of which $10.0M is finance lease ROU assets — applying a 50-60% recovery to tangible PP&E yields roughly $83-99M. Cash/equivalents of $95.5M recover at par; short-term investments (mutual funds) of $43.1M at par or near-par; net AR of $28.6M at 90-95% haircut yields $25.7-27.2M. Operating lease ROU assets of $23.7M receive zero recovery in liquidation. The liability stack at face value is the driver of negative recovery: accounts payable and accrued liabilities of $105.6M, a $34.4M litigation accrual (current), total debt of $58.8M gross ($49.4M Term Loan A + $9.4M revolver draw), operating lease liabilities of $25.3M (undiscounted $31.7M remaining obligations that do not extinguish), finance lease liabilities of $10.6M (undiscounted $12.3M), deferred tax liabilities net of $9.3M, and redeemable noncontrolling interest of $26.1M (redemption obligation that sits ahead of common equity). The single most material change versus the prior filing (December 31, 2025) is the $34.4M litigation accrual now tagged under LossContingencyAccrualCarryingValueCurrent — this represents a step-change in the liability stack, driven by a $35.5M net increase in litigation expenses recognized in Q3 FY2026 corporate G&A. Total G&A for the nine-month period reached $133.4M vs. $94.2M in the comparable prior-year period, with Q3 alone at $76.5M vs. $38.6M in Q3 FY2025 — nearly all of the Q3 increment attributable to litigation accruals. The Adjusted EBITDA addback for litigation costs and settlements was $54.1M for the nine months ended March 31, 2026. The litigation accrual does not extinguish in a wind-up scenario. Debt outstanding declined marginally from $59.4M at December 31, 2025 to $58.8M at March 31, 2026 on scheduled amortization. Operating lease undiscounted obligations declined from $33.3M to $31.7M as leases roll. The OBBBA-related Medicaid rate pressure and California PACE moratorium are balance-sheet-neutral in this period but represent contingent structural headwinds to the revenue base underpinning any enterprise value. Net cash from operations was $43.4M for the nine-month period, a positive but insufficient offset to the permanent liability accruals. Filing discusses the $34.4M litigation accrual in MD&A and Note 9 but the specific contingency quantum is only XBRL-tagged at the current-period aggregate level; granular per-matter exposure is not separately tagged.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...